As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

If you said diabetes, you're right -- a new study finds diabetes costs $101 billion annually in diagnosis and treatment and ...

The data will be aggregated and regularly published by Hims in order to provide proof to the FDA that the shortages of the ...

Research and Development (R&D) Expenses: R&D expenses were $16.0 million for the three months ended September 30, 2024, as compared to $14.0 million for the same period in 2023. The increase was ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...

Since Novo Nordisk and Eli Lilly’s medications have been approved ... of the Medicines Act and could incur penalties and be ...

Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs ...

Novo Nordisk actually did those studies and we followed ... and I think there's a lot of stressful jobs in the world, not ...

Also worth noting, the trial did not involve titration—a dose increase period currently required for Eli Lilly’s Zepbound and ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Polen Global Growth Fund initiated a new position in Oracle and did not eliminate any positions. Volatility re-emerged in the ...